ERBB2 and non-small cell lung carcinoma: However, given the rarity of many genomic alteration in NSCLC (as for example BRAFV600E, HER2, ROS1, NTRK) and the incidence of each of the concurrent mutations, a registry would be strongly advisable as the best method of developing larger cohorts of patients to further investigate the role of concurrent mutations.